Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials-Reference-Cited by-同舟云学术

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

Published:2012-11-13 Issue:1 Volume:19 Page:225-235
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Giessen Clemens,Laubender Ruediger Paul,Ankerst Donna Pauler,Stintzing Sebastian,Modest Dominik Paul,Mansmann Ulrich,Heinemann Volker

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;ESMO Open;2024-09

2. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies;European Journal of Cancer;2024-02

3. Future Directions and Challenges in Overcoming Drug Resistance in Cancer;Drug Resistance in Cancer: Mechanisms and Strategies;2024

4. Impact of Primary Tumor Sidedness on Prognosis and Anti-EGFR Antibody Efficacy in BRAF-Mutant Metastatic Colorectal Cancer: A Pooled Analysis of AIO Studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI;2024

5. A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial;International Journal of Radiation Oncology*Biology*Physics;2023-11